Company Overview
Amanta Healthcare Limited (BSE: 544502, NSE: AMANTA) reported strong financial performance for FY2025-26 alongside regulatory disclosures for its upcoming 31st Annual General Meeting.
Financial Performance
Amanta delivered robust FY26 results with revenue of ₹288 crores (5% YoY growth), EBITDA of ₹63 crores (22% margin), and net profit of ₹15 crores representing 42% year-on-year growth. The company significantly improved its financial position, reducing debt-to-equity ratio from 3.43x in FY23 to 1.06x in FY26 and achieving a debt service coverage ratio of 1.01x. Basic EPS stood at ₹4.33 for the year.
Capital Markets Activity
The company successfully completed its Initial Public Offering in September 2025, raising ₹126 crores through a fresh issue of 1 crore equity shares at ₹126 per share. IPO proceeds utilization shows ₹4.77 crores deployed for SteriPort manufacturing expansion out of ₹7 crores allocated, with delays attributed to deferred supplier payments and machinery order finalization.
Operational Highlights
Amanta achieved 96% overall capacity utilization with SteriPort contributing approximately 42% of operational revenue. The company operates in 21 export markets with 47 products registered across 120 international jurisdictions. Strategic initiatives include expanding SteriPort capacity from 6.6 crore to 12 crore units annually and commissioning a 10.8 MW captive solar plant expected to generate annual savings of ₹9 crores.
Corporate Governance and AGM
The company will hold its 31st Annual General Meeting on September 16, 2026 via video conferencing. Agenda items include adoption of financial statements, reappointment of director Nimesh P Patel, appointment of secretarial auditors, and revision of remuneration for Managing Director Bhavesh Girishbhai Patel. The board recommends no dividend for FY26.
Risk Factors and Contingencies
Contingent liabilities total ₹16.99 crore, primarily comprising ₹16.59 crore in GST disputes related to input tax credit issues and ₹28.52 lakhs in Drug Price Control Order matters. The company has unfulfilled export obligations of US$41.40 lakhs under the Advance License Scheme with potential custom duty liability of ₹713.92 lakhs.
Corporate Social Responsibility
Amanta exceeded its CSR obligation, spending ₹28.72 lakhs against the required ₹14.99 lakhs on healthcare activities, education, and women empowerment initiatives.
Outlook and Strategic Initiatives
The company continues to pursue PIC/s and EU Annex 1 compliance for regulated market access while expanding manufacturing capabilities. Management expects to complete ongoing capex projects by FY2027, positioning the company for sustained growth in both domestic and international markets.